Jönsson P E, Malmberg M, Ericsson M, Ryden S
Department of Surgery, Helsingborg Hospital, Sweden.
Anticancer Res. 1991 Mar-Apr;11(2):877-9.
Weekly dose Adriamycin was given prospectively as first line chemotherapy in a phase II study including 76 patients with evaluable advanced breast cancer. The response rate (CR+PR) was 24 percent (18/76) and a further 41 per cent (31/76) of the patients achieved stable disease (NC). Mean time to progression for responders was 17 months and for those with stabilized disease 10 months. Mean time to progression for all patients was 8.8 months and overall mean survival time 16 months (2-55+). Side effects were well tolerable; myelosuppression was registered in 27 percent and alopecia requiring a wig in 24 percent. In three patients cardiotoxicity was registered after 1,190 mg, 1,480 mg and 1,780 mg respectively. This low dose regimen seems effective and well comparable regarding time to progression with multidrug regimens, including doxorubicin.
在一项II期研究中，对76例可评估的晚期乳腺癌患者前瞻性地给予阿霉素每周剂量作为一线化疗。缓解率（完全缓解+部分缓解）为24%（18/76），另有41%（31/76）的患者病情稳定（疾病稳定）。缓解者的平均进展时间为17个月，病情稳定者为10个月。所有患者的平均进展时间为8.8个月，总体平均生存时间为16个月（2 - 55 +）。副作用耐受性良好；27%的患者出现骨髓抑制，24%的患者脱发需要佩戴假发。3例患者分别在接受1190毫克、1480毫克和1780毫克阿霉素后出现心脏毒性。这种低剂量方案似乎有效，在进展时间方面与包括阿霉素在内的多药方案相当。
